Boyd Peter E., Chief People Officer at Aquestive Therapeutics ($AQST), made four open market sales of company shares over the last year, totaling $337 thousand. His most recent sale occurred on March 10, 2026. These transactions rank 7,325th among 11,678 insiders by sale value, well below the average of $8.6 million across 6.4 sales per insider. He recorded no open market purchases.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 9, 2026 | Aquestive Therapeutics, Inc. | $AQST | Boyd Peter E. | Chief People Officer | A | Non-Qualified Stock Option (right to buy) | 42500 | $4.29 | 42,500.0000 | 122,003,113 | 9999.99% | 0.03% |
| March 10, 2026 | Aquestive Therapeutics, Inc. | $AQST | Boyd Peter E. | Chief People Officer | S | Common Stock | 29814 | $4.17 | 338,509.0000 | 122,003,113 | 8.09% | 0.02% |
| March 9, 2026 | Aquestive Therapeutics, Inc. | $AQST | Boyd Peter E. | Chief People Officer | A | Common Stock | 80000 | $0.00 | 368,323.0000 | 122,003,113 | 27.75% | 0.07% |
| Dec. 4, 2025 | Aquestive Therapeutics, Inc. | $AQST | Boyd Peter E. | Chief People Officer | A | Common Stock | 20000 | $0.00 | 288,323.0000 | 122,003,113 | 7.45% | 0.02% |
| Oct. 15, 2025 | Aquestive Therapeutics, Inc. | $AQST | Boyd Peter E. | See Remarks | S | Common Stock | 10000 | $7.00 | 268,323.0000 | 98,871,369 | 3.59% | 0.01% |
| Sept. 26, 2025 | Aquestive Therapeutics, Inc. | $AQST | Boyd Peter E. | See Remarks | S | Common Stock | 10000 | $6.30 | 278,323.0000 | 98,871,369 | 3.47% | 0.01% |
| Sept. 5, 2025 | Aquestive Therapeutics, Inc. | $AQST | Boyd Peter E. | See Remarks | S | Common Stock | 15000 | $5.30 | 288,323.0000 | 98,871,369 | 4.95% | 0.02% |
| March 7, 2025 | Aquestive Therapeutics, Inc. | $AQST | Boyd Peter E. | See Remark | A | Non-Qualified Stock Option (right to buy) | 40000 | $0.00 | 40,000.0000 | 98,871,369 | 9999.99% | 0.04% |
| March 7, 2025 | Aquestive Therapeutics, Inc. | $AQST | Boyd Peter E. | See Remark | F | Common Stock | 6624 | $2.65 | 311,004.0000 | 98,871,369 | 2.09% | 0.01% |
| March 9, 2025 | Aquestive Therapeutics, Inc. | $AQST | Boyd Peter E. | See Remark | F | Common Stock | 7681 | $2.65 | 303,323.0000 | 98,871,369 | 2.47% | 0.01% |
| March 7, 2025 | Aquestive Therapeutics, Inc. | $AQST | Boyd Peter E. | See Remark | A | Common Stock | 80000 | $0.00 | 317,628.0000 | 98,871,369 | 33.67% | 0.08% |
| March 9, 2024 | Aquestive Therapeutics, Inc. | $AQST | Boyd Peter E. | See Remark | F | Common Stock | 8370 | $4.88 | 237,628.0000 | 0 | 3.40% | 0.00% |
| March 7, 2024 | Aquestive Therapeutics, Inc. | $AQST | Boyd Peter E. | See Remark | A | Common Stock | 86250 | $0.00 | 245,998.0000 | 0 | 53.99% | 0.00% |
| March 7, 2024 | Aquestive Therapeutics, Inc. | $AQST | Boyd Peter E. | See Remark | A | Non-Qualified Stock Option (right to buy) | 43125 | $0.00 | 43,125.0000 | 0 | 9999.99% | 0.00% |